Close
Nordic 9Nordic 9

Epidarex Capital (investor - Venture Capital)

United States epidarex.com
See something wrong or missing? Let us know
Offices:Bethesda

Epidarex Capital is a transatlantic venture capital firm backing life science companies in emerging hubs in the US and UK.

Average round investment:25.46M USD
Average number per year:2.8
Distribution: 2024 (4)2023 (2)2022 (3)2021 (2)
Portfolio companies: United Kingdom EpsilogenUnited Kingdom TheolyticsUnited Kingdom Curve Therapeutics See the entire list
Mostly invests in: United Kingdom United Kingdom (11) Health services (11)
See the entire list

Showing 3 of 11 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Epidarex Capital mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Epidarex Capital

Name Criteria
Germany Yabeo
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.8
  • Active last 12 months: Yes
France LBO France
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
United Kingdom SV Health Investors
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
Switzerland Novartis Venture Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.4
  • Active last 12 months: Yes
United States F-Prime Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 3.1
  • Active last 12 months: Yes
United Kingdom HSBC
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 3.1
  • Active last 12 months: Yes
Netherlands BioGeneration Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 3.2
  • Active last 12 months: Yes
United Kingdom Legal & General
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 3.2
  • Active last 12 months: Yes
Ireland Seroba Life Sciences
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
Germany Bosch Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.1
  • Active last 12 months: Yes
Top